Practical Neurology partners with ReachMD to bring you clinical research and advancements that further clinicians' ability to diagnose and treat neurologic conditions.
Can We Delay Alzheimer's Symptoms Before They Begin? Inside the PrevenTRON Trial
Episode description: Dr. Geoff Kerchner, Vice President and Global Head of Neurodegeneration at Roche, Basel, Switzerland, discusses the science behind PrevenTRON, a prevention study evaluating trontinemab in individuals with preclinical Alzheimer disease.
Keywords: trontinemab, Alzheimer's, Alzheimer disease, dementia, mild cognitive impairment, MCI, amyloid-targeting therapies, Roche, PrevenTRON, TRONTIER, brain health, cognitive health
19 Aug 2026
Subcutaneous Lecanemab for Early Alzheimer Disease: Evidence, Safety, and Patient Selection
Dr. Michael Irizarry, Senior Vice-President, Clinical Research, Eisai, Nutley, NJ, discusses the evidence supporting subcutaneous lecanemab for early Alzheimer disease, including dosing, amyloid clearance, and safety monitoring.
17 Jul 2026
Next-Generation CNS Drug Delivery: Brainshuttle Technology and Clinical Implications in Alzheimer Disease
In this episode, Luka Kulic, MD, Vice President and Global Head of Early Clinical Development in Neuroscience and Rare Diseases at Roche, Basel, Switzerland, discusses the investigational Brainshuttle technology, including results from the BrainShuttle AD clinical trials as a treatment for early Alzheimer disease along with the broader implications of enhanced blood-brain barrier drug delivery in neurology.
23 Jun 2026
Advancing MOGAD Care
Episode Description: What do the latest METEOROID trial results mean for neurologists treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)? Michael Levy, MD, Massachusetts General Hospital, Boston, MA, discusses relapse prevention, diagnostic challenges, and the future of MOGAD management with Peter Sguigna, MD, UT Southwestern Medical Center, Dallas, TX.
15 May 2026
Generalized Myasthenia Gravis: Inside the MINT Trial and CD19 B-Cell Therapy Advances
Richard J. Nowak, MD, MS, Associate Professor of Neurology, Yale School of Medicine, Yale University, New Haven, CT and global principal investigator of the Myasthenia Gravis Inebilizumab Trial (MINT), discusses the phase 3 results, highlighting the safety and efficacy of CD19-targeted B-cell therapy for individuals with generalized myasthenia gravis and its impact on outcomes and steroid reduction in real-world practice. Additional details about MINT may be found in the following publication: The New England Journal of Medicine. For more information on the medication discussed in this episode, please refer to the Full Prescribing Information provided by Amgen, last updated 12/2025.
29 Oct 2025
Ocrevus Treatment in Pregnant and Lactating Women with Multiple Sclerosis
Riley Bove, MD, UCSF School of Medicine, San Francisco, CA details results from the MINORE and SOPRANINO studies examining Ocrevus treatment in pregnant and lactating women with multiple sclerosis.
29 Oct 2025
The Use of Intracranial Vessel Wall MRI for the Diagnosis of Vasculitis
Jae W. Song, MD, MS, Associate Professor of Radiology at the University of Pennsylvania, Philadelphia, PA, discusses the diagnostic value of intracranial vessel wall MRI for vasculitis, as well as when clinicians should order this imaging technique and the challenges that may arise.
7 May 2025
New Guidelines for the Assessment of Traumatic Brain Injury
Beth McQuiston, MD, RD, Medical Director, Abbott, Abbott Park, IL, and David Okonkwo, MD, PhD, Professor of Neurological Surgery, University of Pittsburgh, Pittsburg, PA, describe some of the important updates to guidelines for the assessment of traumatic brain injury, including biomarker testing.
22 Mar 2025
The Impact of High Efficacy DMTs on Paramagnetic Rim Lesions
Jack Reeves, PhD, researcher at the University at Buffalo Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY, discusses results of a study which demonstrated high efficacy disease-modifying therapies may help prevent the development of paramagnetic rim lesions and slow the progression of multiple sclerosis.
14 Mar 2025
Proposed Hospital Standards for Parkinson Disease Care Aim to Avoid Preventable Harm
Preventable harm is a serious concern for patients with Parkinson disease who receive care in the hospital setting, even when admitted for reasons other than their diagnosis. Peter Pronovost, MD, PhD, FCCM, Chief Quality and Transformation Officer at University Hospitals Cleveland Medical Center, Cleveland, OH, discusses his work with the Parkinson’s Foundation developing new hospital care standards for reducing medication mismanagement and improper or insufficient care.
22 Jan 2025
Promising Results for Investigational Antisense Oligonucleotide Treatment for Dravet Syndrome
Joseph Sullivan, MD, Professor, UCSF School of Medicine, San Francisco, CA, describes encouraging results from the SWALLOWTAIL and LONGWING studies of an investigational treatment for individuals with Dravet syndrome, including outcomes related to seizure frequency, cognition, and behavior.
19 Dec 2024
Vagus Nerve Stimulation: Effects Beyond the Nervous System
Dr. Stavros Zanos, a leading expert in neurostimulation, uncovers the profound effects of Vagus Nerve Stimulation on diseases beyond the nervous system, revealing new avenues for treatment and research.
20 Nov 2024
The Role of Advanced Genomic Testing in the Diagnosis and Treatment of Neurologic Conditions
GeneDx's Chief Medical Officer Paul Kruszka, MD, shares expert insights on the utility of advanced genomic testing for diagnosing and treating neurologic conditions, empowering physicians with informed treatment decisions.
21 Mar 2024
Physicians with Substance Use Disorder, Part II: Available Treatment and Recovery Options
Chris Bundy, MD, Executive Medical Director, Washington Physicians Health Program, provides an overview of treatment and recovery options available to physicians with substance use disorder, including peer-to-peer support, medication, and Physician Health Programs.
8 Mar 2024
Physicians with Substance Use Disorder, Part 1: Overview and A Personal Journey Through Recovery
Chris Bundy, MD, Executive Medical Director, Washington Physicians Health Program, provides an overview of physician substance use disorder, including prevalence, risk factors, and impediments to recovery as well as details about his own journey with recovery.
8 Mar 2024
Physicians with Substance Use Disorder, Part I: Overview and A Personal Journey Through Recovery
Chris Bundy, MD, Executive Medical Director, Washington Physicians Health Program, provides an overview of physician substance use disorder, including prevalence, risk factors, and impediments to recovery as well as details about his own journey with recovery.
19 Jan 2024
Discussing Disparities in MS Care for Underrepresented Populations
In this episode, Trisham Gyang, MD, Clinical Assistant Professor of Neurology, The Ohio State University Wexner Medical Center, and Gopika Govindan Kutty, MD, Fellow, Department of Neurology, The Ohio State University Wexner Medical Center, provide strategies to assess biologic, genetic, and social factors in patients living with MS to help shrink the gap in care for underrepresented populations.
Reach and audience
Public platform figures. Ratings count people who left a rating, not total listeners.
Apple Podcasts (US)
5.0 / 5
1 ratings
Podcast Authority Score: 11 / 100
A composite of feed quality, social presence, YouTube performance and engagement. Read the methodology.
Quality
12
Social presence
0
YouTube
0
Engagement
27
Contact NeuroFrontiers
Guest appearances
Does not typically book guests
Based on episode analysis; this does not confirm that the show is currently accepting guests.
Host of NeuroFrontiers?
Claim your podcast to manage its listing and keep your show details accurate.
Pod Engine is an independent podcast discovery and analytics service and is not affiliated with or endorsed by this podcast. Artwork and show content belong to their owners. Full legal notice.
Explore this show Podcast research with Pod Engine
